{"count": 2, "results": [{"_id": "32186781", "pmid": 32186781, "pmcid": "PMC7160554", "title": "Potential therapies for residual hepatoblastoma following incomplete ablation treatment in a nude mouse subcutaneous xenograft model based on lncRNA and mRNA expression profiles", "journal": "Oncol Rep", "authors": ["Wang XD", "Peng JB", "Zhou CY", "Que Q", "Li HY", "He Y", "Yang H"], "date": "2020-06-01T00:00:00Z", "doi": "10.3892/or.2020.7545", "meta_date_publication": "2020 Jun", "meta_volume": "43", "meta_issue": "6", "meta_pages": "1915-1927", "score": 50253.39, "text_hl": "Additionally, six compounds (@CHEMICAL_Valproic_Acid @CHEMICAL_MESH:D014635 @@@valproic acid@@@, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, @CHEMICAL_tanespimycin @CHEMICAL_MESH:C112765 @@@tanespimycin@@@, @CHEMICAL_Wortmannin @CHEMICAL_MESH:D000077191 @@@wortmannin@@@, @CHEMICAL_Fulvestrant @CHEMICAL_MESH:D000077267 @@@fulvestrant@@@ and @CHEMICAL_MK_886 @CHEMICAL_MESH:C060893 @@@MK-886@@@) were identified by CMap analysis as potential therapeutic agents for the treatment of residual @<m>DISEASE_Hepatoblastoma</m> @DISEASE_MESH:D018197 @@@HB@@@ tissues. ", "citations": {"NLM": "Wang XD, Peng JB, Zhou CY, Que Q, Li HY, He Y, Yang H. Potential therapies for residual hepatoblastoma following incomplete ablation treatment in a nude mouse subcutaneous xenograft model based on lncRNA and mRNA expression profiles Oncol Rep. 2020 Jun;43(6):1915-1927. PMID: 32186781", "BibTeX": "@article{32186781, title={Potential therapies for residual hepatoblastoma following incomplete ablation treatment in a nude mouse subcutaneous xenograft model based on lncRNA and mRNA expression profiles}, author={Wang XD and Peng JB and Zhou CY and Que Q and Li HY and He Y and Yang H}, journal={Oncol Rep}, volume={43}, number={6}, pages={1915-1927}}"}}, {"_id": "30719114", "pmid": 30719114, "title": "Metformin attenuates hypoxia-induced resistance to cisplatin in the HepG2 cell line.", "journal": "Oncol Lett", "authors": ["Fujita H", "Hirose K", "Sato M", "Fujioka I", "Fujita T", "Aoki M", "Takai Y"], "date": "2019-02-01T00:00:00Z", "doi": "10.3892/ol.2018.9869", "meta_date_publication": "2019 Feb", "meta_volume": "17", "meta_issue": "2", "meta_pages": "2431-2440", "score": 50056.215, "text_hl": "Selective delivery of an effective dose of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ to a @<m>DISEASE_Hepatoblastoma</m> @DISEASE_MESH:D018197 @@@hepatoblastoma tumor@@@ may be achievable and clinically useful with TACE.", "citations": {"NLM": "Fujita H, Hirose K, Sato M, Fujioka I, Fujita T, Aoki M, Takai Y. Metformin attenuates hypoxia-induced resistance to cisplatin in the HepG2 cell line. Oncol Lett. 2019 Feb;17(2):2431-2440. PMID: 30719114", "BibTeX": "@article{30719114, title={Metformin attenuates hypoxia-induced resistance to cisplatin in the HepG2 cell line.}, author={Fujita H and Hirose K and Sato M and Fujioka I and Fujita T and Aoki M and Takai Y}, journal={Oncol Lett}, volume={17}, number={2}, pages={2431-2440}}"}}]}